Evidence map›Paper›PMID 37066316›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Evaluation of Xpert

Achilles Katamba, Willy Ssengooba, James Sserubiri, Derrick Semugenze, Kasule George William, Nyombi Abdunoor, Raymond Byaruhanga, Stavia Turyahabwe, Moses L Joloba

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Achilles KatambaMakerere University, Department of Medicine, school of Medicine, Clinical Epidemiology and Biostatistics Unit, Uganda Implementation Research Consortium, Kampala, Uganda.
Willy SsengoobaMakerere University, Department of Medical Microbiology.
James SserubiriMakerere University, Department of Medical Microbiology.
Derrick SemugenzeMakerere University, Department of Medical Microbiology.
Kasule George WilliamMinistry of Health, National Tuberculosis and Leprosy Programme.
Nyombi AbdunoorMinistry of Health, National Tuberculosis and Leprosy Programme.
Raymond ByaruhangaMinistry of Health, National Tuberculosis and Leprosy Programme.
Stavia TuryahabweMinistry of Health, National Tuberculosis and Leprosy Programme.
Moses L JolobaMakerere University, Department of Medical Microbiology.
Ministry of Health · MNMakerere University · UGLung Institute · US

Funding

NURTURE:Research Training and Mentoring Program for Career Development of Faculty at Makerere University College of Health SciencesD43TW010132 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI SEWANKAMBO, NELSON K · 2015 to 2019
$4.3M
FIC NIH HHS D43 TW010132
6 · The paper itself

Abstract

Background: Drug-Resistant Tuberculosis (DR-TB) is one of the key challenges toward TB control. There is an urgent need for rapid and accurate drug susceptibility tests (DST) for the most commonly used 1 Design and Methods: In a blinded, laboratory-based cross-sectional study, we set out to validate the performance of the Xpert Results: A total of 100 stored sputum samples were included in this study. Of the samples tested using MGIT960, 65/99 (65.6%) were resistant to INH, 5/100 (5.0%) resistant to FQ and none were resistant to IAs. The sensitivity and specificity, n (%; 95%Confidence Interval, CI) of Xpert Conclusion: There is high sensitivity and specificity of Xpert

Identifiers

PMID37066316
PMCPMC10104194
OpenAlexW4362603802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.